Teva Pharmaceutical Industries Stock Current Liabilities
| TEVA Stock | ILA 5,873 90.00 1.51% |
Teva Pharmaceutical Industries fundamentals help investors to digest information that contributes to Teva Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharmaceutical stock.
Teva |
Teva Pharmaceutical Industries Company Current Liabilities Analysis
Teva Pharmaceutical's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Teva Pharmaceutical Current Liabilities | 13.01 B |
Most of Teva Pharmaceutical's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Teva Pharmaceutical Industries has a Current Liabilities of 13.01 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current liabilities for all Israel stocks is 64.57% lower than that of the firm.
Teva Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Teva Pharmaceutical's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Teva Pharmaceutical could also be used in its relative valuation, which is a method of valuing Teva Pharmaceutical by comparing valuation metrics of similar companies.Teva Pharmaceutical is currently under evaluation in current liabilities category among its peers.
Teva Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X | |||
| Revenue | 14.93 B | |||
| Gross Profit | 6.97 B | |||
| EBITDA | (791 M) | |||
| Net Income | (2.35 B) | |||
| Cash And Equivalents | 2.44 B | |||
| Cash Per Share | 2.21 X | |||
| Total Debt | 19.1 B | |||
| Debt To Equity | 2.26 % | |||
| Current Ratio | 1.01 X | |||
| Book Value Per Share | 7.11 X | |||
| Cash Flow From Operations | 1.59 B | |||
| Earnings Per Share | (0.56) X | |||
| Price To Earnings To Growth | 0.67 X | |||
| Target Price | 11.0 | |||
| Number Of Employees | 34 K | |||
| Beta | 1.22 | |||
| Market Capitalization | 39.95 B | |||
| Total Asset | 44.01 B | |||
| Retained Earnings | 14.99 B | |||
| Working Capital | 5.39 B | |||
| Current Asset | 18.4 B | |||
| Current Liabilities | 13.01 B | |||
| Z Score | 1.2 | |||
| Five Year Return | 2.96 % | |||
| Net Asset | 44.01 B |
About Teva Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.